Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health — EASD 2026

Bagsværd, Denmark, 30 September 2026 — Novo Nordisk today announced new data on how CagriSema works inside both the brain and body, presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026.In a 52-week functional magnetic resonance imaging (fMRI) study, a brain sca…